Coya Therapeutics (NASDAQ:COYA) Now Covered by HC Wainwright

Analysts at HC Wainwright started coverage on shares of Coya Therapeutics (NASDAQ:COYA) in a research note issued to investors on Monday, Benzinga reports. The firm set a “buy” rating and a $18.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 181.25% from the stock’s current price.

A number of other research analysts have also commented on the company. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research report on Wednesday, June 5th. Rodman & Renshaw initiated coverage on Coya Therapeutics in a research report on Thursday, June 13th. They set a “buy” rating and a $18.00 price target for the company.

Coya Therapeutics Trading Up 7.4 %

NASDAQ COYA opened at $6.40 on Monday. Coya Therapeutics has a 1-year low of $3.21 and a 1-year high of $10.69. The stock has a 50-day moving average of $6.34 and a 200-day moving average of $7.60. The firm has a market cap of $93.56 million, a PE ratio of -7.53 and a beta of 0.58.

Coya Therapeutics (NASDAQ:COYA) last released its earnings results on Monday, August 12th. The company reported ($0.19) earnings per share for the quarter. The firm had revenue of $3.43 million during the quarter. As a group, equities research analysts forecast that Coya Therapeutics will post -1.17 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in COYA. Greenlight Capital Inc. grew its holdings in shares of Coya Therapeutics by 172.2% during the 4th quarter. Greenlight Capital Inc. now owns 1,274,026 shares of the company’s stock worth $9,441,000 after acquiring an additional 805,959 shares during the period. Vanguard Group Inc. grew its holdings in shares of Coya Therapeutics by 772.3% during the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after acquiring an additional 750,338 shares during the period. AIGH Capital Management LLC grew its holdings in shares of Coya Therapeutics by 92.6% during the 4th quarter. AIGH Capital Management LLC now owns 1,031,977 shares of the company’s stock worth $7,381,000 after acquiring an additional 496,183 shares during the period. Renaissance Technologies LLC purchased a new position in shares of Coya Therapeutics during the 2nd quarter worth approximately $101,000. Finally, Gilbert & Cook Inc. purchased a new position in shares of Coya Therapeutics during the 2nd quarter worth approximately $61,000. Hedge funds and other institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.